- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02744651
EUS-Endodrill vs. EUS-FNA for Diagnosis of Submucosal Tumors in the Upper GI Tract
Endodrill is a new instrument for biopsy sampling in the GI-channel. The purpose of this study is as follows:
- Compare EUS-guided Endodrill biopsies with endoscopic ultrasound guided fine needle aspiration (EUS-FNA) in terms of ability to establish the correct diagnosis of submucosal tumors in the upper GI tract.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Endodrill is a newly constructed biopsy tool for flexible endoscopic use. It uses a drilling motion within a casing to harvest solid biopsies from tissue through the biopsy channel of a conventional flexible endoscope. It was originally designed for sampling of tissue from submucosal lesions. The investigators first study of the instrument is now finished. Endodrill is safe to use and generates more submucosal tissue compared to biopsies with a conventional biopsy forceps.
In this study the investigators want to compare the Endodrill instrument with FNA (both modalities EUS-guided) in terms of ability to obtain the correct diagnosis of submucosal tumors in the upper GI-tract. Patients diagnosed with suspected submucosal tumors in the upper GI-tract will be enrolled to this study. They will first go through examination with EUS. If the suspicion of a submucosal tumor is confirmed, the investigator will perform both EUS guided FNA and Endodrill biopsies in the same patient.The harvested tissue will be evaluated by senior pathologists to clarify which method that generates most correct diagnosis.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Skane
-
Lund, Skane, Sweden, 22185
- University Hospital of Lund
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- All patients with a suspected submucosal tumor in the upper GI tract that are available for both EUS-guided FNA and Endodrill biopsy
Exclusion Criteria:
- Mental illness
- Extreme co-morbidity
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: EUS-FNA
All patients with a confirmed suspicion of a submucosal tumor in the upper GI tract will be included in this study.
A senior endoscopist will perform multiple passes of EUS-FNA until she/he has collected enough material for the pathologist to establish a possible diagnosis.
|
Please note the text in section "Arm description"
|
Active Comparator: EUS-Endodrill biopsy
All patients who are included in the study will also be examined by a senior endoscopist performing multiple EUS guided passes with the Endodrill biopsy.
The harvested tissue from the tumor will be examined by a pathologist in order to establish a diagnosis.
|
Please note the text in section "Arm description"
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of correct histopathological diagnoses from submucosal tumors in the upper GI tract.
Time Frame: 24 months
|
Number of biopsies with the correct histopathological diagnoses
|
24 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Endodrill III
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastrointestinal Neoplasms
-
Shanghai Juncell TherapeuticsShanghai 10th People's HospitalRecruiting
-
Sun Yat-sen UniversityUnknownGastrointestinal CancersChina
-
H. Lee Moffitt Cancer Center and Research InstituteNovartisCompleted
-
Peking University Cancer Hospital & InstituteActive, not recruitingGastrointestinal CancerChina
-
Novartis PharmaceuticalsActive, not recruitingNeoplasms, Gastrointestinal TractChina, Canada, Estonia, Italy, Turkey, Argentina, Israel, Netherlands, Poland, Russian Federation, Thailand, Brazil, Chile, Hong Kong, Hungary, India, Mexico, Peru, Taiwan, Ukraine, United States, Korea, Republic of, Puerto Rico
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdJiangsu Alphamab Biopharmaceuticals Co., LtdRecruitingAdvanced Gastrointestinal TumorsChina
-
Boehringer IngelheimCompletedGastrointestinal Cancer, MetastaticBelgium, United States, France, Japan, China
-
Memorial Sloan Kettering Cancer CenterCompleted
-
Henan Cancer HospitalUnknownAdvanced Gastrointestinal TumorsChina
-
Taiho Oncology, Inc.CompletedAdvanced Gastrointestinal TumorsUnited States
Clinical Trials on EUS-FNA
-
The Third Xiangya Hospital of Central South UniversityUnknownSolid Pancreatic MassesChina
-
Asan Medical CenterCompletedPancreatic MassesKorea, Republic of
-
Bin ChengCompleted
-
University of Colorado, DenverUS EndoscopyRecruitingPancreatic CystUnited States
-
National Cancer Center, KoreaCompleted
-
American Society for Gastrointestinal EndoscopyMidwest Biomedical Research FoundationUnknownMediastinal or Intra-abdominal Lymphadenopathy, | Pancreatic Masses, | Left Adrenal Masses, | Gastrointestinal Submucosal Lesions, and | Liver MassesUnited States
-
AdventHealthUniversity of Alabama at BirminghamCompletedPancreatic CancerUnited States
-
Mauna Kea TechnologiesUnknownPancreatic Neoplasms | Pancreatic Cancer | Lymphadenopathy | Pancreatic Cyst | Pancreatic Islet Cell Tumors | Pancreatic Adenoma | Lymph NodeFrance
-
Johns Hopkins UniversityBoston Scientific CorporationCompletedPancreatic Solid Lesions | Pancreatic MassUnited States
-
Samsung Medical CenterCompletedPancreatic Mass | Peripancreatic MassKorea, Republic of